Biotin, folic acid, nicotinamide, pantothenic acid, pyridoxine, thiamine, vitamin b12, vitamin b2, vitamin c (Soluvit Novum)
Biotin, folic acid, nicotinamide, pantothenic acid, pyridoxine, thiamine, vitamin b12, vitamin b2, vitamin c
Fresenius Kabi South Africa (Pty) Ltd
Registration
- Applicant
- Fresenius Kabi South Africa (Pty) Ltd
- Certificate holder
- Fresenius Kabi South Africa (Pty) Ltd.
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Soluvit novum EACH 10 ml VIAL CONTAINS BIOTIN 60 ug FOLIC ACID 0,4 mg NICOTINAMIDE 40 mg PANTOTHENIC ACID 15 mg PYRIDOXINE 4 mg THIAMINE HYDROCHLORIDE 3,2 mg VITAMIN B12 5 ug VITAMIN B2 3,6 mg VITAMIN C 100 mg | 10 mlPowder for solution for infusion. | U0200U/22.1.4/200Approved 3 February 2021 | Registered | Not determined | PIPIL |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S3: Vitamin b1
- and derivatives thereof
- in preparations thereof for injection; (S0)
- except in oral preparations or mixtures containing more than 100 mg of Vitamin B1 per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1)
Consolidated Schedules 06 July 2026, lines 4392 to 4397
S3: Vitamin b12
- and derivatives thereof
- in preparations thereof for injection; (S0)
- except in oral preparations or mixtures containing more than 100 µg of Vitamin B12 per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1)
Consolidated Schedules 06 July 2026, lines 4428 to 4433
S3: Vitamin b2
- and derivatives thereof
- in preparations thereof for injection; (S0)
- except in oral preparations or mixtures containing more than 100 mg of Vitamin B2 per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1)
Consolidated Schedules 06 July 2026, lines 4399 to 4404
S3: Vitamin b5
- and derivatives thereof
- in preparations thereof for injection; (S0)
- in oral preparations or mixtures containing more than 200 mg of Vitamin B5 per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1)
Consolidated Schedules 06 July 2026, lines 4414 to 4419
S3: Vitamin b6
- and derivatives thereof
- in preparations thereof for injection; (S0)
- except in oral preparations or mixtures containing more than 100 mg of Vitamin B6 per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1)
Consolidated Schedules 06 July 2026, lines 4421 to 4426
S3: Vitamin c
- in preparations thereof for injection; (S0)
- except in oral preparations or mixtures containing more than 1000 mg of Vitamin C per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1)
Consolidated Schedules 06 July 2026, lines 4435 to 4440
S1: Folic acid
- in oral preparations or mixtures containing more than 500 µg of Folic Acid per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S0)
Consolidated Schedules 06 July 2026, lines 484 to 485
S1: Nicotinamide
- and derivatives thereof, in oral preparations or mixtures containing more than 500 mg of Nicotinamide per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S0)
Consolidated Schedules 06 July 2026, lines 886 to 888
S1: Vitamin b1
- and derivatives thereof
- in oral preparations or mixtures containing more than 100 mg of Vitamin B1 per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0)
- except in preparations thereof for injection. (S3)
Consolidated Schedules 06 July 2026, lines 1149 to 1154
S1: Vitamin b12
- and derivatives thereof
- in oral preparations or mixtures containing more than 100 µg of Vitamin B12 per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0)
- except in preparations thereof for injection. (S3)
Consolidated Schedules 06 July 2026, lines 1177 to 1182
S1: Vitamin b2
- and derivatives thereof
- in oral preparations or mixtures containing more than 100 mg of Vitamin B2 per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0)
- except in preparations thereof for injection. (S3)
Consolidated Schedules 06 July 2026, lines 1156 to 1161
S1: Vitamin b5
- and derivatives thereof
- in oral preparations or mixtures containing more than 200 mg of Vitamin B5 per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0)
- except in preparations thereof for injection. (S3)
Consolidated Schedules 06 July 2026, lines 1163 to 1168
S1: Vitamin b6
- and derivatives thereof
- in oral preparations or mixtures containing more than 100 mg of Vitamin B6 per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0)
- except in preparations thereof for injection. (S3)
Consolidated Schedules 06 July 2026, lines 1170 to 1175
S1: Vitamin c
- in oral preparations or mixtures containing more than 1000 mg of Vitamin C per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0)
- except in preparations thereof for injection. (S3)
Consolidated Schedules 06 July 2026, lines 1184 to 1189
S1: Vitamin h
- and derivatives thereof, in oral preparations or mixtures containing more than 500 µg of Vitamin H per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S0)
Consolidated Schedules 06 July 2026, lines 1196 to 1197
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.